Biofrontera Reports Positive Phase 3 Ameluz PDT Results

An update from Biofrontera ( (BFRI) ) is now available.

On February 9, 2026, Biofrontera announced positive top-line Phase 3 results for its Ameluz photodynamic therapy with the red-light RhodoLED platform in treating mild to moderate actinic keratoses on the extremities, neck and trunk. The multicenter, randomized, double-blind study enrolled 172 patients and was designed to test field-directed treatment over increasingly large skin areas using one or more tubes of Ameluz followed by red-light illumination.

The trial met its primary endpoint of subject complete clearance rate 12 weeks after the last treatment, with Ameluz PDT achieving complete clearance in 45.6% of patients in the full analysis set versus 16.7% for vehicle, and 53.2% versus 22.2% in the per-protocol set. Secondary outcomes showed high lesion clearance rates and strong results by anatomical region, with particularly high clearance on the neck and trunk compared with extremities.

Investigators also reported favorable cosmetic outcomes and high patient satisfaction, with most patients and clinicians rating aesthetic results as good or very good and a large majority indicating they would choose PDT again. Management described the data as a critical milestone that supports expanding Ameluz’s use beyond the face and scalp, potentially enlarging its addressable market across multiple sun-exposed body areas.

Based on these positive Phase 3 findings, Biofrontera intends to seek a U.S. regulatory label expansion for Ameluz to cover actinic keratoses on the extremities, neck and trunk via a supplemental application in 2026. If granted, the broader indication would strengthen the company’s positioning in photodynamic therapy and offer dermatologists a more versatile option for treating high-burden actinic keratosis fields across the body.

The most recent analyst rating on (BFRI) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.

Spark’s Take on BFRI Stock

According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.

The score is held down primarily by weak financial performance—persistent operating losses, continued cash burn, and negative equity. Technicals are mixed and do not provide strong confirmation of a durable uptrend, while valuation is difficult to support given negative earnings and no dividend. Offsetting factors include earnings-call guidance targeting FY2026 cash-flow breakeven and margin improvement from acquiring U.S. rights, but near-term listing/compliance risk remains a notable headwind.

To see Spark’s full report on BFRI stock, click here.

More about Biofrontera

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology, specializing in photodynamic therapy for pre-cancerous and non-melanoma skin conditions. The company commercializes its Ameluz gel in combination with RhodoLED lamp systems for treating actinic keratosis, and runs clinical trials to broaden its indications, including non-melanoma skin cancers and moderate to severe acne.

Biofrontera’s market focus centers on high-burden, sun-induced skin lesions that can progress to invasive cancers, positioning the company in a niche segment of dermatologic oncology. By integrating a drug-device combination and pursuing label expansions, it aims to deepen its presence in the U.S. dermatology market and solidify its role in photodynamic therapy solutions.

Average Trading Volume: 223,474

Technical Sentiment Signal: Sell

Current Market Cap: $9.56M

See more data about BFRI stock on TipRanks’ Stock Analysis page.